Compass Pathways.
mental health care company
- Reports this week
- 0
- Active events
- 0
- Connections
- 39
What's happening
One to three months ago
-
Johnson & Johnson and Compass Pathways are both involved in the advanced psychedelic therapy market, currently submitting applications for COMP360 approval.Some support1 report
-
Guy Goodwin has been appointed Chief Medical Officer at Compass Pathways.Some support1 report
-
Compass Pathways announced that its Phase 3 trial for COMP360 successfully met the primary endpoint.Some support4 reports
-
Compass Pathways ADR trading on the Nasdaq stock exchange.Some support1 report
-
Compass Pathways, NeuroStar, and Greenbrook are facing mixed business signals regarding their business units, with both revenue growth and decline reported.Some support1 report
-
Compass Pathways and LabCorp are two companies operating within the healthcare sector.Some support1 report
Gone quiet
No new reports in 90+ days-
Jefferies Financial Group and Raymond James Financial reaffirmed buy ratings on Compass Pathways stock, which MarketBeat is tracking.Some support2 reports
-
FDA reviews potential accelerated pathways for approval for Compass Pathways.Well supported4 reports
-
Kabir Nath was appointed CEO of Compass Pathways, and Justin Gover joined the company's Board of Directors.Some support8 reports
-
Compass Pathways established its operational footprint as of July 2025, including headquarters in London, offices in New York, and Breakthrough Therapy designation from the FDA.Some support3 reports1 development inside
-
RBC Capital Markets noted disappointing trial results for Compass Pathways, whose drug faces competition from Johnson & Johnson's Spravato.Speculative1 report
-
Compass Pathways received a Zacks rating upgrade on July 9, 2025, due to rising earnings estimates and positive outlook.Speculative1 report
-
A conference (PS2025) was held at the Colorado Convention Center in Denver on July 16, 2025, featuring major announcements from the psychedelic industry.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Compass Pathways this week
News at the entities that move Compass Pathways most-
FDA StructuralVera Therapeutics and the FDA agreed to shift the assessment of a clinical study.Moves Compass Pathways
-
Drug Enforcement Administration StructuralHowell, a former DEA agent, alleges that fentanyl has reached New Mexico.Moves Compass Pathways
-
Cathie Wood TransactionalArk Invest is undergoing valuation model updates while Tesla conducts robotaxi testing in Austin.Moves Compass Pathways
-
TD Cowen Mentioned togetherTruist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.Moves Compass Pathways
-
Jefferies Financial Group Mentioned togetherJefferies Financial Group lowered its shares rating for Gibson Energy on July 31, 2026.Moves Compass Pathways
-
Raymond James Financial TransactionalRaymond James Financial began coverage of Rexford Industrial Realty shares, while Truist Financial lowered its target price on the company's stock.Moves Compass Pathways
Connections
The 20 strongest of 39, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Compass Pathways relies on the FDA for regulatory designations, submissions, and market approval of its therapies.
-
Kabir Nath Structural
Kabir Nath holds the formal role of CEO at Compass Pathways.
-
Drug Enforcement Administration Structural
Compass Pathways' launch is pending regulatory rescheduling by the Drug Enforcement Administration.
-
Guy Goodwin Structural
Guy Goodwin holds the role of Chief Medical Officer at Compass Pathways.
-
Nasdaq Structural
Compass Pathways utilizes Nasdaq's platform for ADR trading.
-
Raymond James Financial Transactional
Raymond James Financial issued a buy rating on Compass Pathways stock.
-
Cathie Wood Transactional
Cathie Wood purchased shares in Compass Pathways as part of her investment strategy.
-
Johnson & Johnson Operational
Johnson & Johnson and Compass Pathways are actively competing in the advanced psychedelic therapy market.
Show all 20 connections
-
MarketBeat Mentioned together
MarketBeat aggregates consensus stock ratings for Compass Pathways.
-
TD Cowen Mentioned together
TD Cowen has provided a 'buy' rating on Compass Pathways, indicating a professional market assessment.
-
Mental Health America Operational
Mental Health America is observed amplifying a campaign related to Compass Pathways' efforts.
-
Morgan Stanley Mentioned together
Morgan Stanley provided an 'overweight' rating and lifted a price objective for Compass Pathways.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provided market coverage of Compass Pathways by restating a buy rating on its stock.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provided financial analysis, including a price target and rating, for Compass Pathways.
-
LabCorp Mentioned together
Both Compass Pathways and LabCorp are identified as medical companies operating within the healthcare sector.
-
Robert F. Kennedy Jr. Shared context
Kennedy has criticized corporate influence within the health sector, where Compass Pathways operates.
-
London Shared context
Compass Pathways is headquartered and operates within London.
-
New York City Shared context
Compass Pathways maintains offices in New York City, establishing a positional link.
-
National Alliance on Mental Illness Mentioned together
The provided evidence does not describe any relationship or coupling between National Alliance on Mental Illness and Compass Pathways.
-
RBC Capital Markets Mentioned together
No direct coupling or co-mention between RBC Capital Markets and Compass Pathways was observed in the provided evidence.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
2 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
7 events- Compass Pathways announced that its Phase 3 trial for COMP360 successfully met the primary endpoint.
- FDA reviews potential accelerated pathways for approval for Compass Pathways.
- Kabir Nath was appointed CEO of Compass Pathways, and Justin Gover joined the company's Board of Directors.
- Compass Pathways established its operational footprint as of July 2025, including headquarters in London, offices in New York, and Breakthrough Therapy designation from the FDA.
- RBC Capital Markets noted disappointing trial results for Compass Pathways, whose drug faces competition from Johnson & Johnson's Spravato.
- Compass Pathways received a Zacks rating upgrade on July 9, 2025, due to rising earnings estimates and positive outlook.
- A conference (PS2025) was held at the Colorado Convention Center in Denver on July 16, 2025, featuring major announcements from the psychedelic industry.